Different Way | GenomeWeb

Different Way

The point of personalized medicine, as the mantra goes, is to bring the right treatment to the right patient at the right time. But getting such tailored therapies approved may mean that how clinical trials assessing their efficacy and safety are conducted needs to be re-thought, writes Susan Young at Technology Review.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.